Instructions for Co-trimoxazole (biseptol)
English product name
CO-Trimoxazole
Release Form
tab. 480 mg: 10 or 20 pcs.
Description Co-trimoxazole
Tablets 1 tab.
sulfamethoxazole 400 mg
trimetoprim 80 mg
10 pcs. - blister packs (1) - cardboard packs.
10 pcs. - blister packs (2) - cardboard packs.
ATC codes
J01EE01 Sulfamethoxazole and trimethoprim
Clinical-pharmacological groups / Group affiliation
Antibacterial sulfanilamide preparation
Active substance
- sulfamethoxazole
- trimetoprim
Pharmaco-therapeutic group Co-trimoxazole
Antimicrobial combined agent
Pharmacodynamics Co-trimoxazole
Combined bactericidal chemotherapeutic agent
The preparation Co-trimoxazole contains two active substances which have a synergistic effect, inhibiting two enzymes that catalyze successive stages of folic acid biosynthesis in microorganisms. Thanks to this mechanism, the bactericidal effect of in vitro is achieved at such concentrations in which the individual components of the preparation have only a bacteriostatic effect. In addition, the drug Co-trimoxazole is often effective against pathogens resistant to one of its components.
Testimony Co-trimoxazole
- Co-trimoxazole should be prescribed only when the doctor believes that the benefit of such therapy exceeds the risk; it is
- necessary to decide whether one effective antibacterial agent is feasible, and to take into account the recommendations of the
- official guidelines on the appropriate use of antibacterial drugs and the local prevalence of resistance to antibacterial drugs.
- Because the sensitivity of bacteria to in vitro antibiotics varies in different geographical areas and over time, local bacterial
- sensitivities should be taken into account when choosing a drug. Co-trimoxazole should be used only for the treatment or
- prevention of infections that are reliably or with a high probability caused by bacteria or other microorganisms sensitive to the
- preparation. In the absence of such information, appropriate antibacterial therapy should be empirically selected in accordance
- with the epidemiological situation and local characteristics of bacterial sensitivity.
- Respiratory tract and ENT infections: acute bronchitis, moderate otitis in children.
- Treatment and prevention (primary and secondary) of Pneumocystis jirovecii-induced pneumonia in adults and children,
- including with severe immunodeficiency.
- Genitourinary tract infections:
- urinary tract infections,
- mild shankr.
- Gastrointestinal infections: typhoid fever and parathif,
- shigellosis (caused by sensitive strains of Shigella flexneri and Shigella sonnei if antibacterial therapy is shown),
- travel diarrhea caused by enteropathogenic strains of Escherichia coli, cholera
- (in addition to replenishing fluids and electrolytes).
- Other infections include infections caused by a range of microorganisms (possibly combined with other antibiotics) such as
- brucellosis,
- acute and chronic osteomyelitis,
- nocardiosis,
- actinomycosis,
- toxoplasmosis,
- and South American blastomycosis.
Method of use and dosage Co-trimoxazole
Inside, after eating, with enough fluids.
The dose is set individually.
Children: three to five years old - 240 mg (two 120 mg tablets) twice a day; six to twelve years - 480 mg (four 120 mg tablets or one 480 mg tablet) twice a day.
Adults and children over the age of 12: 960 mg twice a day, for long-term therapy - 480 mg twice a day. The course of treatment for 5-14 days, in case of severe flow and/or chronic form of the disease, a single dose can be increased by 30-50%,
